China Sky One Medical, Inc. Obtains SFDA Approval to Produce Two New Drugs

HARBIN, China, May 20 /Xinhua-PRNewswire-FirstCall/ -- China Sky One
Medical, Inc. (OTC Bulletin Board: CSKI) ("China Sky One" or "the Company"), a
China based manufacturer, marketer and distributor of pharmaceutical,
medicinal and diagnostic products, announced today that its subsidiary,
Heilongjiang Tianlong Pharmaceuticals, has obtained approvals for two new
drugs; Oxymetazoline Hydrochloride Nasal Drops and Taurine Eye Drops, from the
SFDA.
Oxymetazoline Hydrochloride Nasal Drops is approved for the treatment of
acute and chronic rhinitis, sinusitis and allergic rhinitis. Taurine Eye Drops
is approved for the treatment of acute and chronic conjunctivitis. The
incidences of these diseases in China are extremely high. This is especially
true in regions with colder weather as well as coastal regions.
These approvals bring the total number of China Sky One's products for
externally used drugs to 49 and the total marketed products to 98, making
China Sky One the company with the most comprehensive pharmaceutical product
portfolio in China. The Company is still aggressively seeking approval for
other drugs with large market potential. By the end of 2008, the Company will
have a total 38 new drugs submitted to the SFDA approval.
"Most of the pharmaceutical companies that make these two products in
China do not have strong distribution channels. China Sky One will be able to
quickly commercialize these two drugs and capture at least 10% of the market
share by leveraging our extensive sales network and experienced management
team," said Mr. Yan-qing Liu, Chairman, CEO and Director of China Sky One
Medical, Inc. "We believe that the commercialization of these two products
will provide a steady revenue for China Sky One and further improve our
profitability in the years ahead."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a China based
company engaged in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic kit products. Through its
wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology
Company and Harbin First Bio-Engineering Company Limited the Company
manufactures and distributes over-the-counter pharmaceutical products as its
primary revenue source. For more information, visit
http://www.skyonemedical.com .
Safe Harbor Statement
Certain statements made in the press release constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements can be identified by the use of forward-looking
terminology such as "believe," "expect," "may," "will," "should," "project,"
"plan," "seek," "intend," or "anticipate" or the negative thereof or
comparable terminology. Additional statements that are necessarily
forward-looking in nature also include, without limitation, statements
relating to our research and development activities, expected revenues or
sales margins, results of recent acquisitions and our ability to increase
sales and expand our presence in the global market place, and risks or
uncertainties relating to PRC socioeconomic issues. Such statements typically
involve risks and uncertainties and may include financial projections or
information regarding our future plans, objectives or performance. The Company
cannot provide any assurance that it will be able to establish listing of its
securities on any national or regional securities exchange or market system.
Actual results could differ materially from the expectations reflected in such
forward-looking statements as a result of a variety of factors, including the
inability of the company to meet listing standards of an exchange, risks
associated with the effect of changing economic conditions in The People's
Republic of China, variations in cash flow, reliance on collaborative retail
partners both in China and throughout the world and on new product
development,
variations in new product development, risks associated with rapid
technological change, and the potential of introduced or undetected flaws and
defects in products, and other risk factors detailed in reports filed with the
Securities and Exchange Commission from time to time.
For more information, please contact:

China Sky One Medical, Inc.
Mr. Liao Xiaoqing, CFO
Tel: +86-1591-067-2198
Email: tdrhan@163.com

CCG Elite Investor Relations Inc.
Mr. Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
Website: http://www.ccgelite.com

SOURCE China Sky One Medical, Inc.

Mr. Liao Xiaoqing, CFO of China Sky One Medical, Inc., +86- 1591-067-2198, or
tdrhan@163.com; Mr. Crocker Coulson, President of CCG, +1- 646-213-1915,
crocker.coulson@ccgir.com, for CSKI